Lessons from incretin-based therapy in MASH and obesity

IF 45.9 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-06-27 DOI:10.1038/s41575-025-01096-2

Herbert Tilg, Giovanni Targher

引用次数: 0

Abstract

Glucagon-like peptide 1 receptor agonists are effective pharmacotherapies for the treatment of obesity and related disorders. In metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis, semaglutide improved liver histology over 72 weeks. In another new study, tirzepatide was superior to semaglutide in reducing body weight in individuals with obesity.

查看原文本刊更多论文

以肠促胰岛素为基础的治疗MASH和肥胖的经验教训

胰高血糖素样肽1受体激动剂是治疗肥胖及相关疾病的有效药物疗法。在伴有中度至晚期纤维化的代谢功能障碍相关脂肪性肝炎中，西马鲁肽在72周内改善了肝脏组织学。在另一项新的研究中，替西帕肽在减轻肥胖患者体重方面优于西马鲁肽。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Gastroenterology &Hepatology 医学-胃肠肝病学

CiteScore

52.30

自引率

0.60%

发文量

147

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication. The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information. Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.